Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above 200 Day Moving Average – What’s Next?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.66 and traded as high as $4.41. Cumberland Pharmaceuticals shares last traded at $4.36, with a volume of 33,426 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 6th.

Cumberland Pharmaceuticals Price Performance

The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. The stock has a market cap of $60.90 million, a price-to-earnings ratio of -5.66 and a beta of -0.18. The stock has a fifty day moving average of $4.58 and a two-hundred day moving average of $2.66.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $10.44 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP grew its position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,271 shares during the period. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent SEC filing. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.